GlassScriptPhysician profile
Sidney J Bolch
NPI 1639177595
$5,410.51
in general payments reported to CMS, 2019-2025
30 companies · $751 in 2025
The $751 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $542 · 2021: $524 · 2022: $1,066 · 2023: $743 · 2024: $665 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $914.72 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $609.20 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $439.78 | 2021-2025 | Verquvo, Steglatro |
| Actelion Pharmaceuticals US, INC. | $377.70 | 2019-2025 | Opsumit, Opsynvi |
| Celonova Biosciences, INC. | $346.82 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $310.35 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $281.24 | 2019-2024 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Esperion Therapeutics, INC. | $264.30 | 2020-2025 | Nexletol |
| Philips North America LLC | $199.38 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, Ecc Solutions |
| Janssen Pharmaceuticals, INC | $161.38 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.83 | 2019-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $141.82 | 2019-2025 | Praluent, Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $134.12 | 2019-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $133.00 | 2022 | |
| Recor Medical INC | $121.83 | 2024 | Paradise Renal Denervation System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $117.13 | 2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $114.30 | 2019-2024 | |
| Cvrx, INC. | $113.64 | 2020-2025 | Barostim Neo System |
| Medtronic Vascular, INC. | $82.91 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $76.29 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $66.14 | 2019-2024 | Lifevest |
| Baxter Healthcare | $56.04 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $52.36 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.26 | 2025 | |
| Abiomed | $33.00 | 2024 | Impella |
| Novo Nordisk INC | $19.38 | 2023 | Ozempic, Rybelsus |
| Acist Medical Systems, INC. | $18.25 | 2019 | |
| Bardy Diagnostics, INC. | $15.22 | 2022 | |
| Allergan, INC. | $12.92 | 2019 | |
| Chiesi USA, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Bolch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.